Chronic myelomonocytic leukemia (CMML) is a clonal, hematopoietic stem cell disorder, characterized by sustained peripheral blood (PB) monocytosis and an inherent risk for blast phase (BP) disease [1, 2] . Blast phase, as defined by ≥20% PB or bone marrow (BM) blasts [1] , has a reported incidence ranging from 15 to 29% [1, 2] . Risk factors for CMML-BP have included high-risk karyotype [3, 4] , PB blast % [5, 6] , circulating immature myeloid cells (IMCs) [6] , absolute monocyte count (AMC) >10 × 10(9)/L [5, 6] , ASXL1, RUNX1, NRAS, SETBP1, DNMT3A, and NPM1 mutations [6, 7] . In CMML, while predictors for BP have been identified, not much is known about prognostication, optimal treatment modalities, and survival outcomes. We carried out this large, collaborative, two institution study (Mayo Clinic, Minnesota and the MD Anderson Cancer Center, Texas) with the intent to examine (i) prognostic factors, (ii) survival trends, and (iii) treatment outcomes in patients with CMML-BP. The diagnoses of CMML and CMML-BP were according to the 2016 World Healh Organization (WHO) criteria for hematological malignances [1] . CMML cytogenetic risk stratification was per the Mayo-French cytogenetic stratification system [4] . Overall CMML risk stratification was based on the Mayo prognostic model, GFM model, and the Mayo Molecular Model [5, 6, 8] . Cytogenetic and molecular genetic risk stratification for CMML-BP cases was based on the 2017 European Leukemia Net (ELN) guidelines [9] . Response assessment to therapy was based on the International Working Group (IWG) MDS and MDS/MPN overlap syndrome response assessment criteria [10, 11] , while that for AML was based on the ELN response criteria [9] . Twenty-nine gene panel targeted capture assays were carried out on BM DNA specimens obtained at diagnosis for myeloid-relevant genes by previously described methods [12] . All statistical analyses considered parameters obtained at time of CMML and CMML-BP diagnosis. Differences in the distribution of continuous variables between categories were analyzed by either Mann-Whitney or Kruskal-Wallis test. Patient groups with nominal variables were compared by chi-square test. Cox proportional hazard regression model was used for multivariable analysis. The Stat View (SAS Institute, Cary, NC, USA) statistical package was used for all calculations. One hundred and seventy-one patients with CMML-BP were included in the study; 84 (49%) seen at the Mayo Clinic and 87 (51%) at the MDACC (Supplementary table 1) .
Characteristics at CMML diagnosis
The median age at CMML diagnosis was 69 years (range, 27-90 years), with 64% (n = 110) being male. Cytogenetic information at CMML diagnosis was available in 157 (92%) patients of which, 65 (41%) had an abnormal karyotype (supplementary table 2). Archived DNA at CMML diagnosis was available in 67(39%) patients (Table 1 ) and encountered mutations included; ASXL1 43%, SRSF2 30%, TET2 30%, NRAS 15%, RUNX1 12%, DNMT3A 10%, IDH2 10%, SETBP1 9%, CBL 7%, JAK2V617F 6%, U2AF1, PTPN11, NPM1, and Tp53 4% each, c-KIT, and FLT3 ITD 3% each, KRAS, CSF3R, MPL, SF3B1, ZRSR2, IDH1, and EZH2 1% each, respectively. 
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CMML-BP treatment strategies and responses
Treatment details were available in 157 (92%) patients and included best supportive care 39 (BSC, 25%), HMA therapy 16 (10%), AML-like induction chemotherapy 59 (38%), AML-like induction chemotherapy followed by allogeneic HCT 23 (15%), upfront allogeneic HCT 2 (2%), and clinical trials in 18 (11%) (Supplementary table 4). Twenty-nine (38%) patients had prior 5-azacitidine exposure for a median of 6 cycles (range, 2-24), while 50 (65%) patients had prior decitabine exposure for a median of 12 cycles (range, 1-50), with 2 patients having received both agents sequentially. In the azacitidine-treated patients, 33% achieved a CR, 11% a partial response (PR), 48% had stable disease, while 8% had disease progression on therapy. In the decitabinetreated patients, 60% had a CR, 12% PR, 21% stable disease, while 7% had disease progression on therapy. Among the 8 patients that went on to get post CMML-BP HMA therapy, 4 (50%) had received prior azacitidine with all 4 having stable disease, while 4 (50%) had received decitabine with 50% CR, 25% PR and 25% with stable disease. Twenty-five (16%) patients went on to receive HCT, with 40% being in a CR and 12% having CRi at the time of HCT (supplementary table 5 ). At last follow-up, 19 (76%) deaths were reported, with a median relapse-free survival (RFS) of 7 months and a median OS of 10 months; with no difference in RFS (p = 0.8) or OS (p = 0.7) between patients that received a MA versus RIC. CMML-BP treatment response was assessable in 113 
CMML-BP survival outcomes
After a median follow-up of 4.4 months (range 0-122), 141 (82%) deaths were recorded. Median OS was 6 months with 1-, 3-, and 5-year survival rates of 25%, 9%, and 6%, respectively. Survival trends were similar (p = 0.4) for patients diagnosed prior to and after the year 2006 (Fig. 1a) .
In patients that received AML-like induction chemotherapy (n = 55), survival outcomes were dismal regardless of response (Fig. 1b) . Similarly, with the exception for a modest survival benefit for patients undergoing allogeneic HCT (5-year survival rate 21%), survival with BSC, AMLlike induction chemotherapy alone, HMA and clinical trials was dismal (Fig. 1c) . In the allogeneic HCT group, patients that had ELN adverse risk cytogenetics at CMML-BP had an even shorter survival in comparison to those with ELN intermediate risk cytogenetics (Fig. 1d) . Ninety-two percent of post HCT deaths were due to disease relapse. In univariate analysis of variables recorded at time of CMML-BP, risk factors adversely impacting survival included older age (p = 0.04), lower hemoglobin (p = 0.02), PB blast % (<0.0001), ELN high-risk cytogenetics (p = 0.007), prior exposure to HMA (p = 0.006), failure to achieve CR/CRi (p = 0.0006), and not undergoing HCT (p = 0.0011). Gene mutations, including FLT3-ITD (p = 0.4), cytogenetic clonal evolution (p = 0.3), and molecular clonal evolution (p = 0.4), did not impact survival. In multivariable analysis, only PB blast % (PB blasts ≥ 20%, p = 0.0005, HR 2.2, 95% CI 1.4-3.4), prior exposure to HMA therapy (p = 0.002, HR 1.9, 95% CI 1.2-2.1), ELN high-risk cytogenetics (p = 0.03, HR 1.5 (95% CI 1.1-2.3), and failure to achieve CR/CRi CMML-BP is associated with high morbidity and poor outcomes [2, 6, 12] . In this study of 171 CMML-BP patients, the median OS was 6 months with a 5-year survival rate of 6%. Although with time, advances have occurred in clinical therapeutics; in our study survival in CMML-BP was not significantly different based on the calendar year of diagnosis. CMML-BP patients were treated with a variety of modalities and with the exception for a modest survival benefit with allogeneic HCT (5-year survival rate 21%), survival outcomes with all other modalities remained dismal (5-year survival rates <10%). Eighty-one (47%) patients had prior exposure to HMA with 33% having achieved CR prior to CMML-BP; indicating the ineffectiveness of these agents in altering the natural course of this disease. In a recent study, serial sequencing demonstrated that responses to HMA in CMML were associated with changes in DNA methylation and gene expression, without any changes in the mutational allele burdens [13] .
In the current study, we demonstrate that prior exposure to HMA was an independent factor adversely impacting post CMML-BP survival; although one may argue that these patients already had aggressive disease biology, necessitating the earlier use of HMA. Additional negative prognosticators included ELN high risk cytogenetics, PB blast % ≥20 and failure to achieve CR/CRi with induction chemotherapy. Neither did cytogenetic clonal evolution, nor molecular clonal evolution, impact survival. Although, the achievement of CR/CRi after induction chemotherapy was found to have a favorable impact, the overall durability of response was limited (median OS 9.8 months). Allogeneic HCT was successfully carried out in a small fraction of CMML-BP patients (15%); with patients that had adverse cytogenetic findings at CMML-BP demonstrating a trend toward inferior survival. These data support the earlier use of allogeneic HCT in eligible patients, preferably before blast phase disease. The response rates to HMA use after CMML-BP were strikingly dismal with 0% CR and 17% CRi; suggesting that these patients should not be reexposed to these agents.
In summary, ours is the largest-to-date study, describing the clinical and molecular correlates and dismal outcomes of patients with CMML-BP disease. These results serve as a critical benchmark for future clinical trial design and conduct.
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